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Toward a Better Understanding of...
Induction of IDH2 R140Q Mutation in 
Stem Cells with Doxycycline Increases 
Rate of  Cell Death
Reuben Aaron Hogan
Mentor: David Spencer
Mutations in isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) occur in a variety of 
human cancers. IDH enzymes normally convert isocitrate to alpha-ketoglutarate (aKG) 
in the citric acid cycle. However, the cancer-associated mutations occur at specific 
positions in each gene, including position 140 of IDH2, and lead to the production of 
a novel molecule, R-2-hydroxyglutarate (2HG). 2HG has been shown to result in DNA 
and histone hypermethylation of leukemia samples in comparison to normal cells. To 
understand how this specifically blocks cellular differentiation and allows increased 
proliferation, we set up an experimental model within stem cells.
H9 cells were infected using a lentivirus which delivered DNA containing the 
IDH2 R140Q mutation, the GFP gene, and a promoter region that binds a receptor 
for doxycycline (DOX). When cells are treated with DOX, the receptors diffuse from 
the promoter, allowing transcriptional machinery to take over. The cell then produces 
mutant IDH2; however, induction of IDH2 R140Q kills stem cells instead of causing 
increased proliferation. Our hypothesis is that there is a differential gene expression in 
stem cells from leukemic cells that must be controlled for to use the model.
To test this hypothesis, we generated both an H9 IDH2 R140Q line and a H9 Vector 
line. Both were treated with DOX for at least 2 days and were brought up with untreated 
samples as controls. GFP expression was measured by flow cytometry as an indicator 
of IDH2 R140Q positivity. Cell counts were taken for all conditions (H9 IDH2 and 
H9 Vector ± DOX) at different time points to determine the rate of cell death. RNA 
sequencing was done for all conditions to determine what genes were differentially 
expressed, and analysis was done to compare the expression between samples and with 
leukemia tumor samples as well.
